Compare TG Therapeutics Inc (TGTX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Under Armour Inc Class A — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Under Armour Inc Class A trades at $5.07 (market cap $2.15B). The key difference: TG Therapeutics Inc is far larger — about 4× Under Armour Inc Class A's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| TGTX | UAA | |
|---|---|---|
Market Cap | $8.53B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $8.14 |
52-Week Low | $26.94 | $4.17 |
Enterprise Value | $8.74B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Under Armour (UAA) trades at $5.06, down 3.62% amid bearish technical signals and negative cash flow. The company reported Q2 2026 EPS of $0.05, beating expectations, but faces revenue declines and a net loss of $201 million in 2025. Analyst consensus is mixed with 27% buy ratings and a $6.67 price target, while technical indicators show resistance at $5 with RSI neutral but ADX signaling strong bearish momentum.
UAA's outlook is challenged by weakening revenue and negative profitability, though cost controls and international growth offer some support. Investment opportunity exists if margin improvements translate to sustained earnings, but risks include persistent North America softness and high debt levels. The stock trades near analyst low targets, suggesting limited upside without operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
